{
  "report_rows": [
    {
      "kpi": "Total Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$7.65B vs. cons $7.53B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EPS",
      "prediction": "MISS",
      "answer": "pred ~$0.50 vs. cons $0.59",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Concerts Segment AOI",
      "prediction": "MISS",
      "answer": "pred ~$130M vs. cons ~$165M",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted Operating Income (AOI) growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~10% vs. cons ~10% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 2026 Concerts/Venue Nation seasonal inflection (stadium/amphitheater fan growth skew)",
      "prediction": "UNCHANGED",
      "answer": "guide ~70% of amphitheater growth and all stadium growth in 2H vs. cons ~50-60% assumed (Q3 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Ticketmaster/Ticketing AOI headwind from anti-scalping crackdown",
      "prediction": "LOWER",
      "answer": "guide ~-5% to Ticketing AOI vs. cons ~-3% modeled headwind (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -3.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -1.5,
  "day5_path": "FADE",
  "day5_rationale": "An EPS miss (messy bottom line has been the norm \u2014 3 of last 4 quarters missed) plus any incremental antitrust/post-trial-motion headline risk should trigger an initial negative idiosyncratic reaction, especially given the stock's run to 52-week highs (~$184, +26% YTD) leaving little room for disappointment. However, because management is expected to reiterate the unchanged full-year double-digit AOI framework and confirm the already-flagged Q3/Q4 seasonal inflection (stadiums/amphitheaters), sell-side estimate revisions for the out-periods (Q3/Q4/FY) likely stay largely intact rather than being cut further, causing the initial drop to partially fade over the week as bulls (BTIG/Citizens/Oppenheimer $200-215 PTs) reiterate theses on unchanged guidance. The unresolved antitrust remedy/Tunney Act overhang caps a full recovery, keeping the fade only partial rather than a full round-trip.",
  "day5_confidence": "LOW"
}